Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): An American Society for Radiation Oncology evidence-based guideline  by Tsao, May N. et al.
www.practicalradonc.org
CME
Practical Radiation Oncology (2012) 2, 210–225Special Article
Radiotherapeutic and surgical management for newly
diagnosed brain metastasis(es): An American Society
for Radiation Oncology evidence-based guideline
May N. Tsao MDa,⁎, Dirk Rades MDb, Andrew Wirth MDc, Simon S. Lo MDd,
Brita L. Danielson MDe, Laurie E. Gaspar MD, MBAf, Paul W. Sperduto MD, MPPg,
Michael A. Vogelbaum MD, PhDh, Jeffrey D. Radawski MDi,
Jian Z. Wang PhDn, Michael T. Gillin PhD j, Najeeb Mohideen MDk,
Carol A. Hahn MDl, Eric L. Chang MDm
aDepartment of Radiation Oncology, University of Toronto, Odette Cancer Centre, Toronto, Ontario, Canada
bDepartment of Radiation Oncology, University Hospital Schleswig-Holstein, Luebeck, Germany (ESTRO representative)
cPeter MacCallum Cancer Center, Trans Tasman Radiation Oncology Group (TROG), East Melbourne, Australia
dDepartment of Radiation Oncology, Case Western Reserve University,
University Hospitals Case Medical Center, Cleveland, Ohio
eDepartment of Radiation Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Canada (CARO representative)
fDepartment of Radiation Oncology, University of Colorado, Aurora, Colorado
gUniversity of Minnesota Gamma Knife Center and Minneapolis Radiation Oncology, Minneapolis, Minnesota
hDepartment of Neurological Surgery, Cleveland Clinic, Cleveland, Ohio
iDepartment of Radiation Oncology, Ohio State University, Columbus, Ohio
jDepartment of Radiation Oncology, M.D. Anderson Cancer Center, Houston, Texas
kDepartment of Radiation Oncology, Northwest Community Hospital, Arlington Heights, Illinois
lDepartment of Radiation Oncology, Duke University Medical School, Durham, North Carolina
mDepartment of Radiation Oncology, University of Southern California Keck School of Medicine, Los Angeles, California
nDepartment of Radiation Oncology, Ohio State University, Columbus, Ohio (deceased)
Received 27 October 2011; revised 9 December 2011; accepted 15 December 2011Note: An online CME test for this article can be taken at http://astro.org/MOC.
Conflicts of interest: Before initiation of this Guideline, all members of the Guidelines Task Group were required to complete disclosure statements.
These statements are maintained at the American Society for Radiation Oncology (ASTRO) headquarters in Fairfax, Virginia and pertinent disclosures are
published with the report. The ASTRO Conflict of Interest Disclosure Statement seeks to provide a broad disclosure of outside interests. Where a potential
conflict is detected, remedial measures to address any potential conflict are taken and will be noted in the disclosure statement. Dirk Rades has received
research grants from Merck Serono and Novartis, and serves as a consultant for Amgen and Astra Zeneca. Michael Vogelbaum has received research
funding from Schering-Plough, Genentech, Brainlab, and Astra Zeneca; he owns stock in Johnson and Johnson. Jian Wang has received a prostate cancer
research grant from the Ohio Cancer Research Associates. Expert reviewers were also required to complete disclosure statements, which are maintained at
ASTRO Headquarters. The Task Group Chairs reviewed all disclosures and determined that they were not relevant to the subject matter of the Guideline.
⁎ Corresponding author. Odette Cancer Centre, 2075 Bayview Ave, Toronto, ON M4N 3M5.
E-mail address: may.tsao@sunnybrook.ca (M.N. Tsao).
1879-8500 © 2012 American Society for Radiation Oncology. Published by Elsevier Inc.
doi:10.1016/j.prro.2011.12.004
Open access under CC BY-NC-ND license. 
Brain metastases: An ASTRO guideline 211Practical Radiation Oncology: July-September 2012Abstract
Purpose: To systematically review the evidence for the radiotherapeutic and surgical management
of patients newly diagnosed with intraparenchymal brain metastases.
Methods and Materials: Key clinical questions to be addressed in this evidence-based Guideline
were identified. Fully published randomized controlled trials dealing with the management of
newly diagnosed intraparenchymal brain metastases were searched systematically and reviewed.
The U.S. Preventative Services Task Force levels of evidence were used to classify various options
of management.
Results: The choice of management in patients with newly diagnosed single or multiple brain
metastases depends on estimated prognosis and the aims of treatment (survival, local treated lesion
control, distant brain control, neurocognitive preservation).
Single brainmetastasis and good prognosis (expected survival 3months ormore): For a single brain
metastasis larger than 3 to 4 cm and amenable to safe complete resection, whole brain radiotherapy
(WBRT) and surgery (level 1) should be considered. Another alternative is surgery and radiosurgery/
radiation boost to the resection cavity (level 3). For single metastasis less than 3 to 4 cm, radiosurgery
alone or WBRT and radiosurgery or WBRT and surgery (all based on level 1 evidence) should be
considered. Another alternative is surgery and radiosurgery or radiation boost to the resection cavity
(level 3). For single brain metastasis (less than 3 to 4 cm) that is not resectable or incompletely resected,
WBRTand radiosurgery, or radiosurgery alone should be considered (level 1). For nonresectable single
brain metastasis (larger than 3 to 4 cm), WBRT should be considered (level 3).
Multiple brain metastases and good prognosis (expected survival 3 months or more): For selected
patients with multiple brain metastases (all less than 3 to 4 cm), radiosurgery alone, WBRT and
radiosurgery, orWBRTalone should be considered, based on level 1 evidence. Safe resection of a brain
metastasis or metastases causing significant mass effect and postoperative WBRT may also be
considered (level 3).
Patients with poor prognosis (expected survival less than 3 months): Patients with either single or
multiple brain metastases with poor prognosis should be considered for palliative care with or without
WBRT (level 3).
It should be recognized, however, that there are limitations in the ability of physicians to accurately
predict patient survival. Prognostic systems such as recursive partitioning analysis, and diagnosis-
specific graded prognostic assessment may be helpful.
Conclusions:Radiotherapeutic intervention (WBRTor radiosurgery) is associatedwith improved brain
control. In selected patients with single brain metastasis, radiosurgery or surgery has been found to
improve survival and locally treated metastasis control (compared with WBRT alone).
© 2012 American Society for Radiation Oncology. Published by Elsevier Inc.
Open access under CC BY-NC-ND license. Introduction
Brain metastases represent a significant health care
problem. It is estimated that 20% to 40% of cancer
patients will develop brain metastases during the course
of their illness.1
Systematic reviews based on randomized phase III
controlled trials for the management of single or
multiple brain metastases in adult patients have been
published.1-8 Various treatment modalities exist, includ-
ing whole brain radiotherapy (WBRT), resection, stereo-
tactic radiosurgery, and best supportive care with the use
of dexamethasone. A series of articles performing a
systematic review and evidence-based clinical practice
guidelines have been published from the perspective of
the modalities listed above under the auspices of the
American Association of Neurological Surgeons/Congress
of Neurosurgeons (AANS/CNS).4-8 The conclusions from
this American Society for Radiation Oncology (ASTRO)
Guideline are congruent with the conclusions put forth
by the AANS/CNS. While these articles are important inthat they are modality-based, it was also felt important
to develop guidelines from an international perspective
with international representation on the Brain Metastases
Task Group. Additional key questions are posed (not
necessarily previously addressed) such as prognostic
classification systems, radiotherapy fractionation schemes,
comparison of surgery and radiosurgery, neurocognition
as an outcome variable in decision-making, palliative
supportive care, and radiation sensitizers.
Treatment recommendations are based on patient
factors (such as age, performance status), tumor factors
(such as number and size of brain metastases, tumor
type, extracranial disease activity), and available treat-
ment options (such as access to neurosurgery or
stereotactic radiosurgery).
This Guideline builds on the previous ASTRO Health
Services Research Committee publication, “The American
Society for Therapeutic Radiology and Oncology
(ASTRO) evidence-based review of the role of radiosur-
gery for brain metastases.”1 This present guideline has
been endorsed by the CNS.
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Process
The Guidelines Subcommittee of the Clinical Affairs
and Quality Committee, in accordance with established
ASTRO policy, recruited a Task Group composed of
recognized experts in the fields of radiotherapy, surgery,
and radiosurgery for brain metastases. These experts
represent radiation oncology, neurosurgery, physics, out-
comes, and health services research. The Task Group was
asked to systematically review the literature on the
radiotherapeutic and surgical management for patients
with newly diagnosed metastatic disease to the brain.
In June 2009, the ASTRO Board of Directors approved
a proposal to develop a Guideline on radiotherapeutic and
surgical management for newly diagnosed brain metasta-
ses. In January 2010, the Board authorized the Task Group
membership. The Task Group participated in a series of
communications by e-mail and conference calls to review
the relevant publications, to discuss controversial issues,
and formulate the Guidelines contained herein. The Task
Group agreed by consensus on the various recommenda-
tions based on the randomized trials and relevant
publications. The initial draft of the manuscript was
reviewed by 3 expert reviewers and was placed on the
ASTRO website during the month of April 2011 for public
comment. Upon integration of the feedback, the document
was then submitted to the ASTRO Board of Directors for
their final review and approval in October 2011.Literature search
MEDLINE (1966-Nov. 3, 2010), EMBASE (1980-
2010 week 46), and the CENTRAL databases (issue 4,
2010) were searched (Appendix 1). The search strategies
resulted in 1826 publications, 597 publications, and 425
publications fromMEDLINE, EMBASE, and CENTRAL,
respectively (search strategy courtesy of the Cochrane
Library). Only randomized phase III trials pertinent to the
management of newly diagnosed brain metastases were
included. Trials dealing with the use of WBRT, surgery,
radiosurgery, chemotherapy, radiosensitizers, and pallia-
tive care alone were considered. Trials that examined the
use of prophylactic cranial irradiation were excluded. A
total of 36 randomized controlled trials were retrieved.
One trial was excluded as it was published in abstract form
in the year 2000 but never fully reported.9 Two duplicate
publications of the same trial10,11 were included.
Lead representatives from international radiation on-
cology groups, ASTRO, Canadian Association of Radia-
tion Oncology (CARO), European Society for Therapeutic
Radiology and Oncology (ESTRO), and Trans-Tasman
Radiation Oncology Group (TROG), reviewed the 36
retrieved trials.As a result of feedback received from public comments,
the literature search was further expanded to include
nonrandomized studies (prospective or retrospective)
dealing with the use of either radiosurgery or fractionated
radiation to the postoperative surgical cavity. The MED-
LINE (1947 to May week 2, 2011) search resulted in 1549
nonrandomized publications and EMBASE (1980-2011
week 20) gave 3721 nonrandomized publications. The
CENTRAL search resulted in 0 randomized controlled
trials. Titles and abstracts were screened and a final total of
15 relevant publications were retrieved.
Of note, all the radiosurgery trials used frame-based
single fraction radiosurgery techniques with either a linear
accelerator or gamma knife unit.
Management options were graded by the level of
evidence available using the U.S. Preventative Services
Task Force levels.12 Due to the lack of high-quality
studies, management of patients with recurrent metastatic
disease to the brain is not included in this report.
The U.S. Preventative Services Task Force levels of
evidence12 are as follows.
Level I: Evidence obtained from at least 1 properly designed
randomized controlled trial.
Level II-1: Evidence obtained from well-designed controlled
trials without randomization.
Level II-2: Evidence obtained from well-designed cohort or
case-controlled analytic studies, preferably from more than 1
center or research group.
Level II-3: Evidence obtained from multiple time series with
or without the intervention.
Dramatic results from uncontrolled trials might also be
regarded as this type of evidence.
Level III: Opinions of respected authorities, based on clinical
experience, descriptive studies or reports of expert committees.
The medical management issues associated with brain
metastases will not be addressed by this Guideline as they
are outside the scope of this review. Optimal follow-up
brain imaging for patients with brain metastases has not
been evaluated using high-quality trials. Based on expert
opinion, in patients with good prognostic features and
where there is potential for future salvage brain metastases
treatment, enhanced magnetic resonance imaging follow-
up every 2 to 4 months should be considered.Results
Table 1 and Table 2 summarize common scenarios
related to patients presenting initially with either single or
multiple brain metastasis(es). These tables include not
only the level 1 evidence but also other treatment options
based on panel opinion and supported by literature of
lower quality evidence.
Table 1 Single brain metastasis—initial management
Prognostic
category ( a)
Other
features
Treatment options (evidence grade)
references
Clinical benefit
S LC WB control Neurocognition
Good prognosis Complete
resection
possible
If brain metastasis ≤3-4 cm:
Expected survival
3 mo or more
• Surgery and WBRT (level 1)10,11,22,23,42,43,b ✓ ✓ ✓
• Radiosurgery and WBRT (level 1)51,53 ✓ ✓ ✓
• Radiosurgery alone (Level 1)23,54 ✓ ✓
• Surgery with radiosurgery/radiation boost
to the resection cavity with or without
WBRT (level 3)26-41,b
✓ ✓ (with WBRT)
If brain metastasis N3-4 cm:
• Surgery and WBRT (level 1)10,11,22,23,42,43,b ✓ ✓ ✓
• Surgery with radiosurgery/radiation
boost to the resection cavity with or without
WBRT (level 3)26-41,b
✓ ✓ (with WBRT)
Good prognosis Not
resectable
If brain metastasis ≤3-4 cm:
Expected survival
3 mo or more
• Radiosurgery and WBRT (level 1)51,53 ✓ ✓ ✓
• Radiosurgery alone (level 1)23,54 ✓ ✓
If brain metastasis N3-4 cm:
• WBRT (level 3), with consideration of
biopsy, if primary unknown59,85,86
✓ ✓ ✓
Poor prognosis • WBRT (level 3)59,85 ✓ ✓
Expected survival
less than 3 mo
• Palliative care without WBRT (level 3)59,85
KPS, Karnofsky performance status; LC, local control; S, survival; WB, whole brain; WBRT, whole brain radiotherapy.
Surgery may be favored if the diagnosis is uncertain (eg, no known primary cancer or remote history of cancer and no known extracranial metastases
or metastasis).
a Prognostic category based on known prognostic factors (see clinical question 1, references 13-21).
b Excluding radiosensitive histologies (eg, small cell lung cancer, leukemia, lymphoma, germ cell tumor). A 6%-9% minority of patients in
Radiation Therapy Oncology Group (RTOG) 9508 trial had small cell lung cancer.
Brain metastases: An ASTRO guideline 213Practical Radiation Oncology: July-September 2012The questions and guideline statements regarding the
radiotherapeutic and surgical management for newly
diagnosed brain metastases are listed below.
1. What prognostic factors are important for
assessing and managing patients with newly
diagnosed brain metastases?
Interpretative summary
Several prognostic indices have been reported in the
literature13-21 for survival duration among patients with
newly diagnosed brain metastases. These are useful in
categorizing patients into survival time strata for treatment
decisions, for predicting the results of therapeutic in-
terventions, and for comparing treatment results.
The Radiation Therapy Oncology Group (RTOG)
devised 3 prognostic groups using recursive partitioning
analysis13,14 based on 1200 patients treated on prospec-
tive clinical trials with WBRT alone or additionally withradiosensitizers: class I, patients with Karnofsky perfor-
mance status (KPS) ≥70 years, less than 65 years of age
with controlled primary (3-month stability on imaging or
newly diagnosed), and no extracranial metastases; class
III, KPS b70; class II, All others. Median survival was 7.1
months, 4.2 months, and 2.3 months for class I, II, and III,
respectively.
Brain metastases are a heterogeneous population.
The purpose of the graded prognostic assessment
(GPA) was to identify significant diagnosis-specific
prognostic factors in an updated era (1985-2007) as
compared with the RTOG recursive partitioning
analysis (RPA) (1979-1993). The original GPA was
based on 4 criteria15: age, KPS, number of brain
metastases, and presence or absence of extracranial
metastases. Each of the 4 criteria is given a score of 0,
0.5, or 1.0 and these 4 scores are summed to determine the
GPA score. Patients with the best prognosis have a GPA
score of 4.0. The authors established this prognostic index
based on 1960 patients treated with WBRT alone, WBRT
and radiosensitizers, or WBRT and radiosurgery in the
Table 2 Multiple brain metastases-initial management
Prognostic
category ( a)
Other features Treatment options
(evidence grade) references
Clinical benefit
S LC WB control Neurocognition
Good prognosis All brain
metastases
≤3-4 cmb
• Radiosurgery and WBRT (level 1)51,53 ✓ ✓
Expected survival
3 mo or more
• Radiosurgery alone23,54 (level 1) ✓ ✓
• WBRT (level 1)59,85 ✓ ✓
Good prognosis Brain metastasis/
metastases
causing significant
mass effect c
• Safe surgical resection of the
brain metastasis/metastases causing
significant mass effect and
postoperative WBRT (level 3)25,b
✓ ✓
Expected survival
3 mo or more
• WBRT (level 3)59,85 ✓ ✓ ✓
Poor prognosis • WBRT (level 3)59,85 ✓ ✓
Expected survival
less than 3 mo
• Palliative care without
WBRT (level 3)59,85
KPS, Karnofsky performance status; LC, local control; S, survival; WB, whole brain; WBRT, whole brain radiotherapy.
Surgery may be favored if the diagnosis is uncertain (eg, no known primary cancer or remote history of cancer and no known extracranial metastases
or metastasis).
a Prognostic category based on known prognostic factors (see clinical question 1, references 13-21).
b Excluding radiosensitive histologies (eg, small cell lung cancer, leukemia, lymphoma, germ cell tumor). A 6%-9% minority of patients in RTOG
9508 trial had small cell lung cancer.
c The maximum number or total volume of brain metastases best treated with radiosurgery (or surgery) is unknown. Randomized trials which
have examined the use of radiosurgery, included selected patients with up to 4 brain metastases, while retrospective reports document use of
radiosurgery that exceed 4 brain metastases.52,55 A retrospective study25 suggested that surgery significantly improves survival if all brain
metastases can be removed.
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prospective clinical trials.
The GPA was then refined based on a multi-
institutional analysis of 4259 other patients with brainTable 3 Diagnosis-specific GPA15,20,21
GPA Significant prognostic
factors
NSCLC/SCLC 0 0
Age N60 50-
KPS b70 70-
ECM Present —
#BM N3 2-
Melanoma/RCC 0 1
KPS b70 70-
#BM N3 2-
Breast cancer 0 0
KPS b60 6
ER/PR/Her2 Triple negative
Age ≥ 70 b7
GI 0 1
KPS b70 7
ECM, extracranial metastases; ER, estrogen receptor; GPA, graded progn
KPS, Karnofsky performance status; #BM, number of brain metastases; N
renal cell carcinoma; SCLC, small cell lung cancer.metastases treated with surgery, WBRT, radiosurgery,
or various treatment combinations. New diagnosis-
specific prognostic indices (diagnosis-specific graded
prognostic assessment) were defined based only on theGPA scoring criteria
.5 1
60 b50
80 90-100
Absent
3 1
2
80 90-100
3 1
.5 1.0 1.5 2.0
0 70-80 90-100
ER/PR + Her2 - ER/PR – Her2 + Triple positive
0
2 3 4
0 80 90 100
ostic assessment; Her2, human epidermal growth factor receptor 2;
SCLC, non-small cell lung cancer; PR, progesterone receptor; RCC,
Table 4 Median survivals stratified by diagnosis and diagnosis-specific GPA score for patients with newly diagnosed brain
metastases15,20,21
Diagnosis Diagnosis-specific GPA
GPA: 0-1 GPA: 1.5-2.0 GPA: 2.5-3.0 GPA: 3.5-4.0
Overall median
survival (mo)
Median
survival (mo)
Median
survival (mo)
Median
survival (mo)
Median
survival (mo)
NSCLC 7.0 3.0 5.5 9.4 14.8
SCLC 4.9 2.8 4.9 7.7 17.1
Melanoma 6.7 3.4 4.7 8.8 13.2
Renal cell 9.6 3.3 7.3 11.3 14.8
GI 5.4 3.1 4.4 6.9 13.5
Breast 13.8 3.4 7.7 15.1 25.3
Total 7.2 3.1 5.4 9.6 16.7
GI, gastrointestinal; GPA, graded prognostic assessment; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer.
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individual diagnosis.20 A subsequent analysis of 400
breast cancer patients refined the breast-GPA scoring
system.21
Table 3 shows the GPA scoring criteria for each of the
significant prognostic factors by diagnosis. Table 4
shows the associated range of median survival by GPA
and diagnosis.
Other prognostic indices such as the score index for
radiosurgery, the basic score for brain metastases, the
Golden grading system, and the Rades prognostic scoring
system have also been published.16-19
Caveats
Most published randomized trials that deal with the
management of patients with brain metastases included
patients with various primary cancers (non-small cell lung
cancer, breast cancer, etc). Physicians should consider
histology-specific indices in regard to clinical decision
making. The use of histology-specific indices help guide
estimated prognosis, useful in deciding on whether
aggressive therapies (eg, radiosurgery, surgery) for
selected patients should be considered (Tables 1 and 2).
At present, there are insufficient level 1 data to recommend
protracted WBRT schedules for certain histologies or
higher radiosurgery doses for “radioresistant” lesions
(such as melanoma, renal cell carcinoma). Future clinical
trials should consider these histology-specific indices for
purposes of stratification.
It should be noted that the original RTOG RPA
system did not find histology to be statistically
significant for survival prediction. However, the revised
GPA has found histology to be statistically significant
based on retrospective data in a more recent era (1985-
2007) compared with the database used to derive the
RTOG RPA (1979-1993). The difference may be due to
newer and more effective chemotherapy used to treat
systemic disease.Newly diagnosed brain metastases: Single
brain metastasis, role for surgery
2. For patients with single brain metastasis
(excluding radiosensitive histologies such as
small cell lung cancer, leukemia, lymphoma,
and germ cell tumor), does surgical resection
and whole brain radiotherapy improve survival
or brain control compared with whole brain
radiotherapy alone or compared with surgical
resection alone?
Interpretative summary
For selected patients with good performance status
(eg, KPS ≥70), limited extracranial disease, and a
resectable brain metastasis, complete resection of the
single brain metastasis improves the probability of
extended survival. The addition of postoperative whole
brain radiotherapy improves treated brain metastasis
control and overall brain control without improving
overall survival or duration of functional independence.
These interpretations are consistent with the AANS
guidelines on the use of surgery.5Phase III randomized trials evidence summary
WBRT and surgery versus WBRT alone
Three randomized controlled trials10,11,42,43 examined
the use of WBRT with or without resection for a single
brain metastasis. [References 10 and 11 are duplicate
publications of the same trial]. Two of the 3 trials10,11,43
found significant improvement in survival with the
addition of surgery to WBRT as compared with
WBRT alone.
The benefit for surgery may be lost in patients with
poor prognostic factors such as advanced extracranial
disease or lower performance status. Decreased median
216 M.N. Tsao et al Practical Radiation Oncology: July-September 2012survival was reported in 2 randomized trials10,11,42 in
patients with a greater systemic involvement of their
primary malignancy. Noordijk et al10 reported a 5-month
median survival in patients with progressive systemic
disease in both the WBRT plus surgery versus WBRT
alone arms. Patients with stable systemic disease had a
12-month survival with WBRT and surgery versus 7
months with WBRT alone. Mintz et al42 reported a
significant difference (P = .009) in the Cox regression
analysis for mortality in patients having extracranial
metastases versus no evidence of primary tumor (risk
ratio 2.3). Forty-five percent of the patients in the study
by Mintz et al42 had extracranial metastases compared
with only 37.5% in the trial by Patchell et al43 and
31.7% in the trial by Vecht et al.11
WBRT and surgery versus surgery alone
Two randomized trials22,23 have been completed that
found a significant improvement in brain control (primary
endpoint) in patients treated with WBRT and surgery as
compared with surgery alone. The first trial22 showed that
postoperative WBRT significantly prevented brain recur-
rence at the site of the original metastasis (10% vs 46%,
P b .001) and at other sites in the brain (14% vs 37%, P b
.01). The authors found no difference in survival with the
use of WBRT and surgery versus surgery alone, although
the study was not powered for survival (a secondary
endpoint of this trial).22
The second trial,23 the European Organization for
Research and Treatment of Cancer (EORTC) 22952-
26001 study, found that WBRT reduced the 2-year relapse
at the initial site of surgery from 59% to 27% (P b .001),
and at new sites from 42% to 23% (P = .008). In addition,
salvage therapies were used more frequently after
observation, compared with after WBRT.23
Caveats
There are 2 completed randomized trials that examine
WBRT and surgery versus surgery alone.22,23 The first
trial22 was small and not powered for survival. The second
trial by the EORTC23 included patients randomized to
receive postoperative WBRT. A total dose of 30 Gy in 10
fractions at 3 Gy per fraction within 6 weeks of surgery
was administered.
The Trans-Tasman Radiation Oncology Group trial
(TROG 98.05) was closed early due to poor accrual.24 The
accrual target was a total of 130 patients. The authors
reported on the 9 patients randomized to observation after
surgery or radiosurgery and 10 patients randomized to
WBRT after surgery or radiosurgery for single brain
metastasis. However, no conclusions could be made from
this severely underpowered study.
No prospective studies have evaluated whether resec-
tion of more than one metastasis conveys meaningful
clinical benefit. A retrospective case control seriessuggests the hypothesis that resection of multiple metas-
tases may convey a similar benefit as conferred by
resection of a single brain metastasis.25 Furthermore, the
benefit of excising multiple brain metastases causing mass
effect has not been definitively proven with level 1
evidence. However, it was felt by the guideline authors
that safe resection of multiple brain metastases causing
mass effect should be included as an option for good
prognosis patients.
There is a lack of level 1 evidence relating to the use
of surgery and radiation boost to the surgical cavity with
or without WBRT, although there are publications (with
lower level of evidence) supporting its use.26-41 Fourteen
publications27-40 reported on the use of surgery and local
radiation (radiosurgery in 10 series and conformal
fractionated radiation therapy in 4 series), with the
rationale to defer or avoid WBRT, without compromis-
ing survival. One publication reported on the use of
surgery, WBRT, and radiosurgery to the surgical cavity,
with the rationale to maximize whole brain and local
tumor bed control.26
However, due to the paucity of randomized data, it is
unknown whether the omission of postoperative WBRT
(with a strategy of close radiographic and clinical
follow-up and the use of salvage radiosurgery or
WBRT at relapse) reduces neurocognitive decline
compared with patients undergoing immediate postoper-
ative WBRT. On the other hand, in a post hoc analysis
of a randomized trial, distant brain metastases recurrence
(a higher risk with radiosurgery alone) may have a
bigger impact on neurocognitive decline.57Newly diagnosed brain metastases: Single
brain metastasis, surgery versus radiosurgery
3. Is survival or brain control different in selected
patients with single brain metastasis (excluding
radiosensitive histologies such as small cell lung
cancer, leukemia, lymphoma, and germ cell
tumor) treated with surgery or radiosurgery?
Interpretative summary
There have been no high quality randomized trials that
have assessed whether selected patients with a small single
brain metastasis, in surgically accessible sites, should
undergo radiosurgery or resection. Adding WBRT did not
improve overall survival or functional independence.
Evidence summary
WBRT and surgery versus radiosurgery alone
One trial44 randomized patients with single (less than
3 cm) resectable brain metastasis to resection plus WBRT
versus radiosurgery alone. Due to poor patient accrual, the
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surgery and WBRT arm and 31 patients in the radiosur-
gery alone arm. This trial was too underpowered for any
conclusions to be made.WBRT and radiosurgery versus WBRT and surgery
One randomized trial examined the use of radiosur-
gery and WBRT versus surgery and WBRT.45 This trial
was closed due to slow accrual. Results were reported
for 11 patients randomized to radiosurgery and WBRT
and 10 patients randomized to surgery and WBRT.
Unfortunately, the trial was too underpowered to make
any conclusions.
There have been 2 retrospective series46,47 and 2
retrospective matched pair analyses48,49 that examined
the use of WBRT and radiosurgery versus WBRT and
surgery for a single brain metastasis. These publications
suggested no difference in overall survival between the
2 study groups.Radiosurgery for “radioresistant” histologies
A phase II trial of radiosurgery for 1 to 3 newly
diagnosed brain metastases (4 cm or less in maximum
dimension) from histologies (renal cell carcinoma, mela-
noma, and sarcoma) that historically have been deemed
radioresistant to fractioned external beam radiotherapy,
was reported by the Eastern Cooperative Oncology
Group.50 Thirty-one eligible patients were treated with
radiosurgery alone. Three-month intracranial failure with
radiosurgery alone was 25.8%; in-field failure rate at 3
months was 19.3%.
Distant intracranial failure rate at 3 months was
32.2%. Survival was consistent with other published
series of similar patients treated with surgery, radiosur-
gery, WBRT, or a combination of these therapies. The
intracranial relapse rate was moderately high in this study
of patients treated with radiosurgery alone. Whether
surgery has better local control or survival as compared
with radiosurgery for “radioresistant” single brain
metastasis could not be answered by this study due to
lack of direct comparisons with a surgical group.
Caveats
In good prognosis patients with single brain
metastasis (less than 3 to 4 cm in maximum dimension
and amenable to gross total resection), either surgery or
radiosurgery may be considered. Surgery may be
favored in patients with unknown primary, or in
patients with single brain metastasis causing significant
mass effect. In good prognosis patients with single brain
metastasis less than 3 to 4 cm in maximum dimension
(in eloquent brain areas not amenable to safe total
resection or in patients who are unfit for surgery),
radiosurgery may be considered.Newly diagnosed brain metastases: Single or
multiple brain metastasis(es), WBRT with or
without radiosurgery boost
4. Is there a survival or brain control difference in
patients treated with WBRT and radiosurgery
boost versus WBRT alone?
Interpretative summary
For good prognosis patients with single brain metasta-
ses (less than 4 cm in size, in patients with good
performance status and controlled extracranial disease),
the use of radiosurgery added to WBRT improves
survival, treated brain lesion control, and overall brain
control as compared with WBRT alone.
In good prognosis patients with multiple brain
metastases (all less than 4 cm in size and up to 4 brain
metastases in number), radiosurgery boost when added to
WBRT improves treated brain lesion and overall brain
control as compared with WBRT alone. As there is no
survival advantage with radiosurgery added to WBRT in
patients with multiple brain metastases, WBRT alone
may be considered.
One randomized trial51 (RTOG 9508) that included
patients with up to 3 brain metastases found an
improvement in KPS and decreased steroid use at 6
months with the use of radiosurgery boost added to
WBRT. These interpretations are consistent with the
AANS guidelines on the use of radiosurgery boost.7
Phase III randomized trials evidence summary
WBRT alone versus WBRT and radiosurgery boost
The multi-institutional, cooperative RTOG 9508 trial51
examined the use of WBRT and radiosurgery boost (n =
167) versus WBRT alone (n = 164). This trial included
selected patients with 1 to 3 newly diagnosed brain
metastases with a maximum diameter of 4 cm (for the
largest lesion) and additional lesions not exceeding 3 cm in
diameter. Median survival was significantly improved in
patients with single brain metastasis treated with radio-
surgery boost (6.5 months) as compared with 4.9 months
in patients treated with WBRT alone. Higher response
rates at 3 months and better control of treated lesions at 1
year were observed in the WBRT and radiosurgery group
versus WBRT alone (82% vs 71%, P = .01).
One single institution fully published trial53 stopped at
an interim evaluation of 60% accrual (14 patients
randomized to WBRT alone and 13 patients randomized
to WBRT plus radiosurgery). There was no survival
benefit with the use of radiosurgery boost as compared
with WBRT alone in patients with multiple brain
metastases. Patients treated with WBRT and radiosurgery
boost were reported to have better brain control versus
those patients treated with WBRT alone.
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None of the trials have examined validated quality of
life outcomes with patients managed with WBRT alone
versus WBRT and radiosurgery boost. Given no
expected survival benefit, either option of WBRT
alone with possible salvage treatment or upfront
WBRT and radiosurgery boost may be offered for
selected patients with multiple brain metastases. It is
unclear from these published trials whether there is
benefit with radiosurgery boost to more than 4 lesions.
However, there are level 3 data on patients undergoing
radiosurgery for 4 or more intracranial metastases
suggesting a survival benefit, and that total intracranial
volume rather than number of brain metastases may be the
more important predictor of survival.52 At present, there
are insufficient high-quality data on whether certain
histologies benefit from the use of radiosurgery to treat
more than 4 intracranial metastases.
When new brain metastases are seen on the planning
scan the day of radiosurgery, it may be reasonable to
proceed and complete the radiosurgical procedure to all the
lesions visualized even if they exceed a total of 4 brain
metastases. Alternatively, not performing radiosurgery and
proceeding with WBRT would also be considered a
reasonable option in these patients.Newly diagnosed brain metastases: Single or
multiple brain metastasis(es), radiosurgery
alone versus WBRT and radiosurgery
5. Is there survival, brain control difference, or
neurocognitive difference in patients treated
with radiosurgery alone versus WBRT
and radiosurgery?
Interpretative summary
Selected patients with brain metastasis(es) may be
treated with radiosurgery alone. A further alternative is
WBRT and radiosurgery boost. A third option for selected
patients with multiple brain metastases is WBRT alone.
There have been no convincing survival differences
among the 3 options listed above, although none of the
trials have been adequately powered to detect anything
other than very large survival differences.
More trials are needed to assess whether there are
differences in neurocognitive and quality of life outcomes
when WBRT is omitted in selected patients who are
treated with radiosurgery alone. There is level 3 evidence
that the increased risk of brain recurrence with a strategy
of radiosurgery alone (if patients are not monitored and
followed adequately) may be associated with symptom-
atic recurrence, which may not recover fully despite
salvage treatment.88Evidence summary
Radiosurgery alone versus WBRT and radiosurgery
One fully published trial56 reported on the use of
radiosurgery alone versus WBRT and radiosurgery in
selected patients with 1 to 4 brain metastases. The number
of patients with single brain metastases (n = 68) was too
small to perform meaningful subset analyses.
As such, results were reported for both single and
multiple brain metastases patients. No overall survival
difference between the 2 groups was found, with a median
survival of 7.5 months (WBRT and radiosurgery) versus
8 months (radiosurgery alone) (P = .42).
However, the 12-month brain tumor recurrence rate was
48.6% in the WBRT and the radiosurgery group compared
with 76.4% for the radiosurgery alone group (P b .001).
Deterioration in mini-mental score examination
(MMSE) occurred in 14 of 36 WBRT and radiosurgery
patients (39%) versus 12 of 46 radiosurgery alone patients
(26%; P = .21), and there was no difference in actuarial
curves of freedom-from-3-point drop in MMSE (P = .73).
Among patients with MMSE decline, the average duration
until deterioration of the MMSE was 16.5 months in the
WBRT and radiosurgery group as compared with 7.6
months in the radiosurgery alone group (P = .05). The
shorter duration to neurocognitive decline (as measured
by the MMSE) was felt by the authors to be attributable to
the increased risk of brain relapse in the radiosurgery
alone group.57 It should be noted, however, that the
MMSE is a poor measure of neurocognition as it lacks
adequate sensitivity.58
Chang et al54 reported a randomized trial that examined
patients with 1 to 3 brain metastases treated with WBRT
and radiosurgery versus radiosurgery alone. The study was
stopped according to early stopping rules on the basis that
there was a high probability (96%) that patients randomly
assigned to receive WBRT and radiosurgery were more
likely to show a decline in learning andmemory at 4months
compared with patients assigned to receive radiosurgery
alone. At 4 months, patients treated with WBRT and
radiosurgery had measurable decline in learning and
memory as compared with patients treated with radiosur-
gery alone (52% vs 24%, respectively) despite higher rates
of local and distant brain control in patients treated with
WBRT and radiosurgery. It remains to be reported whether
neurocognitive outcomes are different between the strategy
of radiosurgery alone versus WBRT and radiosurgery at
different time points (other than 4 months).
Additionally, there was a survival difference between
the 2 arms not readily explained by treatment selection,
raising the possibility of inadvertent randomization or
selection differences between the 2 groups. An imbalance
in the arms of the trial with respect to medications (such as
anti-seizure medications and benzodiazepines) may also
affect neurocognitive outcomes.
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Radiosurgery or surgery alone versus WBRT and
radiosurgery or surgery
The EORTC 22952-26001 trial23 included patients
with 1 to 3 brain metastases. Three hundred fifty-nine
patients were recruited. One hundred ninety-nine patients
underwent radiosurgery and 160 underwent surgery. For
the radiosurgery group, 100 patients were allocated to
post-radiosurgery observation and 99 patients were
allocated to post-radiosurgery WBRT. In the surgery
group, 79 patients were allocated to postsurgery
observation and 81 patients were allocated to adjuvant
WBRT. Patients eligible for radiosurgery had 1 to 3
metastases of solid tumors (small cell lung cancer,
lymphoma, leukemia, myeloma, and germ cell tumors
were excluded) and brain metastasis size ≤3.5 cm in
diameter for a single lesion (≤2.5 cm for 2 to 3 lesions).
A complete resection was required for patients who
underwent surgery.
Overall survival (10.9 months vs 10.7 months) was
similar in both arms (P = .89). WBRT reduced the 2-year
relapse rate both at initial sites (surgery: 59% to 27%, P b
.001; radiosurgery: 31% to 19%, P = .040) and at new sites
(surgery: 42% to 23%, P = .008; radiosurgery: 48% to
33%, P = .023). In well-performing patients with stable
systemic disease and 1 to 3 brain metastases, treated with
initial radiosurgery or surgery, WBRT can be withheld if
serial imaging for follow-up is performed. For patients
undergoing surgery for a single brain metastasis, postop-
erative local irradiation is an option that should be
investigated as adjuvant irradiation substantially reduces
the risk of tumor bed recurrence.
Caveats
There is a suggestion based on 1 randomized trial54 that
omission of WBRT after radiosurgery for single brain
metastasis is associated with better neurocognitive out-
comes based on formal neurocognitive testing. More trials
addressing the question of neurocognitive outcomes in the
setting of radiosurgery alone and omission of upfront
WBRT are needed.
These radiosurgery trials assessed selected patients with
small oligometastases to the brain (up to 4 metastases). It is
unknown if there is a cutoff for the maximum number of
targets appropriate for radiosurgery. Total target volume as
well as number of targets may be important for safety and
efficacy. A prospective nonrandomized series of patients55
with 1 to 10 brain metastases treated with initial
radiosurgery (without WBRT) required less than 10 cc
volume for the largest tumor and less than 15 cc total
tumor volume. Median survival was 0.83 years, 0.69
years, 0.69 years, 0.59 years, and 0.62 years for 1, 2, 3-4,
5-6, and 7-10 metastases, respectively.A phase II trial of radiosurgery for 1 to 3 newly
diagnosed brain metastases from histologies (renal cell
carcinoma, melanoma, and sarcoma), which historically
have been deemed radioresistant to fractioned external
beam radiotherapy, was reported by the Eastern Cooper-
ative Oncology Group50 (ECOG) as discussed previously.
Because the intracranial relapse rate was moderately high
in this study using radiosurgery alone (25.8% at 3 months
and 48.3% at 6 months), the authors concluded that
delaying WBRT may be appropriate for some subgroups
of patients with “radioresistant” histologies, but routine
avoidance of WBRT should be approached judiciously.
Whether WBRT should be routinely omitted in radiosur-
gery eligible patients with “radioresistant” histologies
remains controversial. There is level 3 evidence that the
increased risk of brain relapse with radiosurgery alone may
be associated with symptomatic recurrences that may not
be reversible with salvage brain treatment.88 In this ECOG
trial, the actuarial incidence of failure within the
radiosurgery field at 3 months was 19.3% and at 6 months
was 32.2%. The brain relapse rate and radiosurgery failure
rate in the ECOG trial were similar to the radiosurgery
alone arm in the Aoyama et al,56 Kocher et al,23 and
Chang et al54 trials.
The trials reported have examined the use of
radiosurgery alone versus WBRT and radiosurgery
boost. There have been no trials that have examined
patients treated with radiosurgery alone versus
WBRT alone.
Newly diagnosed brain metastases: Multiple
brain metastases
6. What is the role of comfort measures or
palliative supportive care alone versus WBRT in
patients with multiple brain metastases?
Interpretative summary
For selected patients with poor life expectancy (less
than 3 months), the use of whole brain radiotherapy may or
may not significantly improve symptoms from brain
metastases. Comfort measures only, or short course (20
Gy in 5 daily fractions) whole brain radiotherapy, are
reasonable options.
Evidence summary
WBRT plus supportive care versus supportive
care alone
Only 1 older randomized trial,59 performed in the pre-
computed tomographic era, compared WBRT plus
supportive care versus supportive care alone (oral
prednisone). Median survival in the prednisone alone
arm was 10 weeks as compared with 14 weeks in the
combined arm (P value not stated).
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(Quartz)87 that randomizes patients to optimal supportive
care using dexamethasone versus optimal supportive care
using dexamethasone and whole brain radiotherapy for
patients with inoperable brain metastases from non-small
cell lung cancer. Outcomes of interest include quality of
life, overall survival, and side effects.
Caveats
There are consistent predictors for poor survival of brain
metastases patients that include poor performance status
and active uncontrolled disease.13-21 Until better therapy is
available for these poor prognostic patients, supportive
comfort measures without WBRT can be considered.
7. What is the optimal WBRT dose
fractionation schedule?
Interpretative summary
No differences in overall survival or symptom control
have been demonstrated among the commonly used
fractionation schemes, including 30 Gy in 10 daily
fractions or 20 Gy in 5 daily fractions. Other common
dose fractionation schedules of WBRT are 37.5 Gy in 15
daily fractions and 40 Gy in 20 daily (or twice daily)
fractions. This interpretation is consistent with the AANS
guideline on whole brain radiotherapy.4
Evidence summary
Altered WBRT dose fractionation schedules
Numerous trials have examined various dose fraction-
ation schedules of WBRT.60-69 No altered dose fraction-
ation scheme has shown improvement in either survival or
symptom control (neurologic functional status, neurologic
symptom relief, palliative index, or performance status) as
compared with 20 Gy in 5 fractions or 30 Gy in 10 fractions
of daily WBRT. One trial randomized patients of good
performance status with brain metastases not suitable for
surgical excision to either 40 Gy in 20 fractions of 2 Gy
twice daily versus 20 Gy in 5 daily fractions.68 There was
no difference in median survival (19 weeks in both arms).
Another randomized trial examined the use of 40 Gy in 20
twice daily fractions versus 20 Gy in 4 daily fractions.69
The primary endpoint of brain progression favored patients
treated with 40 Gy in 20 twice daily fractions (44% vs 64%,
P = .03). The secondary endpoint of death from brain
progression was no different between the 2 groups, P = .17.
The authors concluded that intracranial disease control was
improved in patients treated with 40 Gy in 20 twice daily
fractions as compared with 20 Gy in 4 daily fractions.
Caveats
Differences in neurocognitive outcomes have not been
well studied among the different fractionation schemes.These trials also did not examine different dose
fractionation schedules in the setting of single brain
metastasis treated with surgery. In addition, optimal
dose fractionation schedules of WBRT were not
examined in the setting of upfront WBRT with
radiosurgery or in the setting of WBRT at the time
of salvage after radiosurgery alone.
8. What is the role of WBRT and radiosensitizers
versus WBRT alone in the management of
patients with brain metastases?
Interpretative summary
There is no evidence of survival benefit with the use of
radiosensitizers and whole brain radiotherapy.
Evidence summary
WBRT plus radiosensitizers versus WBRT alone
There have been a few randomized trials70-76 that have
examined the use of radiosensitizers (lonidamine, metro-
nidazole, misonidazole, bromodeoxyuridine, motexafin
gadolinium, and efaproxyn or RSR-13). Overall, no
radiosensitizer has improved survival.
Although, the use of motexafin gadolinium was
reported to reduce neurologic progression in patients
with non-small cell lung cancer metastatic to the brain,76
the U.S. Food and Drug Administration did not approve
the use of motexafin gadolinium for non-small cell lung
cancer patients with brain metastases in 2007.
A subset analysis of breast cancer patients treated with
RSR-13 andWBRT was reported to show an improvement
in survival and quality of life as compared with WBRT
alone.70 However, the subsequent larger trial designed
specifically with breast cancer patients failed to show
benefit with the use of RSR-13 and WBRT.71 In 2004, the
U.S. Food and Drug Administration Oncologic Drugs
Advisory committee did not recommend approval of RSR-
13 as an adjunct to WBRT in patients with brain
metastases from breast cancer.
Caveats
More trials are needed to assess the role (if any) of
novel radiosensitizers in patients with brain metastases.
9. What is the role of chemotherapy and WBRT?
Interpretative summary
Although chemotherapy trials reported improved
brain response rates with the use of combined chemo-
therapy and WBRT, this was at the cost of toxicity and
no overall survival advantage was found with the
addition of chemotherapy.77-82 There currently is no
high quality evidence to support the routine use of
chemotherapy in the management of brain metastases.
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Chemotherapy and WBRT
There have been 8 trials examining the use of
chemotherapy for brain metastases.77-84 The chemother-
apy agents used were chloroethylnitrosoureas, teniposide,
fotemustine, temozolomide, thalidomide, and topotecan.
One trial examined the use of early versus delayed WBRT
with chemotherapy in patients with metastatic non-small
cell lung cancer.83 No survival difference was seen
between early versus delayed WBRT with chemotherapy.
Another trial84 examined the use of primary chemotherapy
for newly diagnosed non-small cell lung cancer with
synchronous brain metastases (with delayed WBRT at
brain relapse) versus WBRT administered first. No
survival difference was reported between the 2 arms.
Caveats
Further trials are needed to assess the role of
chemotherapy (including novel systemic agents) in the
management of patients with brain metastases.Conclusions
Treatment options for brain metastases more than 30
years ago were limited to steroids and whole brain
radiotherapy and rarely surgery. Management options
today have expanded to include comfort measures
(including the use of steroids), WBRT and, in selected
patients, surgery or radiosurgery. Optimal management
depends on patient factors (such as age, performance
status), tumor factors (such as extracranial cancer activity,
as well as number, size, location, and histopathology of
brain metastases) and available treatment options (such as
experienced radiosurgery services and neurosurgeons).
The most important endpoint should be the deciding
factor for which treatment is most appropriate. For selected
patients with single brain metastasis, the use of surgery or
radiosurgery has been shown to improve survival and this
should be the primary consideration.
Treatment options which have been shown to improve
whole brain control (such as the use of WBRT) or local
brain control (such as the use of radiosurgery) without
survival benefit for selected multiple brain metastases
patients are more difficult in terms of best treatment
choice. The most important outcome likely is quality of
life (taking into account the morbidity of symptomatic
brain recurrence and the morbidity of treatment such as
neurocognitive decline, which may be associated with the
use of WBRT or the side effects associated with the
prolonged use of dexamethasone). Quality of life has
inconsistently been measured in these trials and drop-outs
are a problem with assessing this endpoint.Numerous research opportunities exist to improve
outcomes (survival, quality of life, brain control, and
neurocognitive function) not only in the initial manage-
ment of patients with brain metastases but also in the area
of salvage treatment.Acknowledgments
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MEDLINE search strategy:
Medline Ovid 1966 to Nov. 3, 2010
222 M.N. Tsao et al Practical Radiation Oncology: July-September 20121. exp Brain Neoplasms/
2. ((brain or brainstem or intracranial or posterior
fossa) adj3 (cancer⁎ or carcinom⁎ or tumor⁎ or
tumour⁎ or neoplasm⁎)).mp.
3. 3 1 or 2
4. exp Neoplasm Metastasis/ or metastas⁎.mp.
5. Radiotherapy/
6. Radiotherapy, Adjuvant/
7. (radiotherapy or radiat⁎ or radiosurg⁎).mp.
8. Combined Modality Therapy/
9. Radiosurgery/
10. gamma knife.mp.
11. or/5-10
12. 3 and 4 and 11
13. randomized controlled trial.pt.
14. controlled clinical trial.pt.
15. randomized.ab.
16. placebo.ab.
17. radiotherapy.fs.
18. randomly.ab.
19. trial.ab.
20. groups.ab.
21. or/13-20
22. 12 and 21
23. limit 22 to yr = ”1966 - 2010”
24. (animals not (humans and animals)).sh.
25. 23 not 24
key:
mp = title, original title, abstract, name of substance
word, subject heading word, unique identifier
pt = publication type
ab = abstract
fs = floating subheading
sh = subject heading
EMBASE search strategy:
Embase Ovid 1980 to 2010 week 46
1. exp Central Nervous System Tumor/
2. exp brain cortex/
3. ((brain or brainstem or intracranial or posterior
fossa) adj3 (neoplasm⁎ or cancer⁎ or carcinoma⁎ or
tumor⁎ or tumour⁎)).mp.
4. or/1-3
5. Brain Metastasis/ or metastas⁎.mp.
6. 4 and 5
7. exp radiosurgery/
8. multimodality cancer therapy/
9. Radiotherapy/
10. Cancer radiotherapy/
11. (radiotherap⁎ or radiosurg⁎).mp.
12. gamma knife.mp.
13. radiat⁎.mp.
14. or/7-13
15. 6 and 14
16. random⁎.ti,ab.17. factorial⁎.ti,ab.
18. (crossover⁎ or cross over⁎ or cross-over⁎).ti,ab.
19. placebo⁎.ti,ab.
20. (doubl⁎ adj blind⁎).ti,ab.
21. (singl⁎ adj blind⁎).ti,ab.
22. assign⁎.ti,ab.
23. allocat⁎.ti,ab.
24. volunteer⁎.ti,ab.
25. crossover procedure/
26. double blind procedure/
27. randomized controlled trial/
28. single blind procedure/
29. or/16-28
30. 15 and 29
31. animal/ or nonhuman/ or animal experiment/
32. human/
33. 31 and 32
34. 31 not 33
35. 30 not 34
36. limit 35 to yr = ”1980 - 2010”
key:
mp = title, abstract, subject headings, heading word,
drug trade name, original title, device manufacturer, drug
manufacturer name
ti = title
ab = abstract
CENTRAL search strategy:
CENTRAL Issue 4, 2010
#1. MeSH descriptor Brain Neoplasms explode all trees
#2. brain⁎ near/3 (cancer⁎ or carcinoma⁎ or tumor⁎ or
tumour⁎ or neoplasm⁎)
#3. brainstem near/3 (cancer⁎ or carcinoma⁎ or tumor⁎
or tumour⁎ or neoplasm⁎)
#4. intracranial near/3 (cancer⁎ or carcinoma⁎ or tumor⁎
or tumour⁎ or neoplasm⁎)
#5. posterior fossa near/3 (cancer⁎ or carcinoma⁎
tumor⁎ or tumour⁎ or neoplasm⁎)
#6. (#1 OR #2 OR #3 OR #4 OR #5)
#7. MeSH descriptor NeoplasmMetastasis explode all trees
#8. metastas⁎
#9. (#7 OR #8)
#10. MeSH descriptor Radiotherapy explode all trees
#11. MeSH descriptor Radiotherapy, Adjuvant explode
all trees
#12. radiotherapy or radiat⁎ or radiosurg⁎
#13. MeSH descriptor Combined Modality Therapy
explode all trees
#14. MeSH descriptor Radiosurgery explode all trees
#15. gamma knife
#16. (#7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13
OR #14 OR #15)
#17. (#6 AND #9 AND #16)
#18. (#17), from 1980 to 2010
(Literature search courtesy of the Cochrane Library.)
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